Cancer cell resistance pathways

"Cancer cell resistance pathways" is not the name of a specific molecule or receptor. Instead, this phrase refers broadly to the diverse cellular and molecular mechanisms by which cancer cells evade the effects of therapeutic agents, commonly termed drug resistance. Major molecular resistance pathways encompass a wide range of genes, receptors, enzymes, transporters, and signaling cascades, such as the PI3K/Akt/mTOR pathway, MAPK pathway, EGFR, oncogenes, tumor suppressor genes, DNA repair mechanisms, autophagy, EMT (epithelial-mesenchymal transition), and cancer stemness. These pathways interact and contribute to cancer's ability to proliferate, survive, and adapt despite therapy, making drug resistance a multifaceted and evolving challenge in oncology[1][2][3][4].\n\n**Note:**\n- "Cancer cell resistance pathways" is a collective term describing cellular processes and not a therapeutic target itself, nor a molecule, receptor, or defined protein family[1][2].\n- To obtain structured data, you must specify a particular molecule, protein, receptor, or defined entity involved in resistance pathways (such as "PI3K", "MDR1", "Epidermal growth factor receptor", etc.) rather than the pathway concept as a whole.

Other names

Drug resistance